Consensus paper on prophylaxis against RSV infection with Palivizumab and post-RSV respiratory tract disease;Konsensuspapier zur prophylaxe der RSV-infektion mit palivizumab und post-RSV-atemwegserkrankung

Monatsschrift fur Kinderheilkunde

Volumn 156, Issue 4, 2008, Pages 381-383

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; ECONOMIC ASPECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG DYSPLASIA; MYOPATHY; NEUROMUSCULAR DISEASE; NEUROPATHY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT INDICATION; VIRUS INFECTION;

EID: 44149084194     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-008-1722-y     Document Type: Conference Paper

References (52)

1. Abman SH, Ogle JW, Butler-Simon N et al. (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113: 826-830
2. Arnold SR, Wang EE, Law BJ et al. (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18: 866-869
3. Boeckh M, Berrey MM, Bowden RA et al. (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 184: 350-354
4. Bont L, Steijn M, Van Aalderen WMC et al. (2004) Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 59: 512-516
5. Bramley AM, Vitalis TZ, Wiggs BR et al. (1999) Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea-pigs. Eur Respir J 14: 1061-1067
6. Buckingham SC, Jafri HS, Bush AJ et al. (2002) A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185: 1222-1228
7. Cole PD, Suh JS, Stiles J et al. (2001) Benign outcome of RSV infection in children with cancer. Med Pediatr Oncol 37: 24-29
8. Döring G, Gusenleitner W, Belohradsky BH et al. (2006) The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks gestational age. Pediatr Infect Dis J 25: 1188-1190
9. Ermers MJJ, Hoebee B, Hodemaekers HM et al. (2007) IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection. J Allergy Clin Immunol 119: 1086-1091
10. Garcia DF, Hiatt PW, Jewell A et al. (2007) Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol 42: 66-74
11. Greenough A, Broughton S (2005) Chronic manifestations of respiratory syncytial virus infection in premature infants. Pediatr Infect Dis J 24: S184-188
12. Henderson J, Hilliard TN, Sherriff A et al. and the ALSPAC Study Team (2005) Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 16: 386-392
13. Hiatt PW, Grace SC, Kozinetz CA et al. (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103: 619-626
14. Horn SD, Smout RJ (2003) Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143: S133-141
15. Hu C, Wedde-Beer K, Auais A et al. (2002) Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol 283: 494-502
16. Kim CK, Chung CY, Choi SJ et al. (2000) Bronchoalveolar lavage cellular composition in acute asthma and acute bronchiolitis. J Pediatr 137: 517-522
17. Kim CK, Kim SW, Park CS et al. (2003) Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J Allergy Clin Immunol 112: 64-71
18. King KA, Hu C, Rodriguez MM et al. (2001) Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 24: 101-107
19. Kneyber MCJ, Steyerberg EW, de Groot R et al. (2000) Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 89: 654-660
20. Law BJ, Langley JM, Allen U et al. (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23: 806-814
21. Lee KK, Hegele RG, Manfreda J et al. (2007) Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: the Canadian Asthma Primary Prevention Study. Pediatr Pulmonol 42: 290-297
22. Madhi SA, Schoub B, Simmank K et al. (2000) Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 137: 78-84
23. Malfroot A, Adam G, Ciofu O et al. for the ECFS Vaccination group (2005) Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 4: 77-87
24. McCormick J, Southern KW (2007) A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 92: 87-88
25. MedImmune Inc. (2007) Synagis® (palivizumab) for intramuscular administration [online]. Available from URL: http://www.synagis.com/content/ sitetools/synagis_pi.pdf [accessed 2007 Jul 8]
26. Meert K, Heidemann S, Abella B et al. (1990) Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 18: 1357-1359
27. Noble V, Murray M, Webb MS et al. (1997) Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 76: 315-319
28. Nuijten MJ, Wittenberg W, Lebmeier M (2007) Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25: 55-71
29. Piedimonte G (2003) Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection. Pediatr Infect Dis J 22: S66-75
30. Piedimonte G, Renzetti G, Auais A et al. (2005) Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr Pulmonol 40: 285-291
31. Red Book® (2006) Report of the Committee on Infectious Diseases, 27th edn. Red Book; American Academy of Pediatrics, Elk Grove Village
32. Resch B, Gusenleitner W, Müller W (2002) The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 30: 193-197
33. Resch B, Berger A, Urlesberger B et al. (2004) Österreichische Empfehlungen zur RSV Prophylaxe bei Frühgeborenen mit Palivizumab - Update 2003. Monatschr Kinderheilkd 152: 223-224
34. Resch B, Pasnocht A, Gusenleitner W et al. (2005) Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 50: 397-403
35. Resch B, Gusenleitner W, Müller W et al. (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 25: 120-122
36. Resch B, Nuijten MJ, Lebmeier M et al. (2006) The cost-effectiveness of palivizumab in Austria. Value Health 9: A94
37. Sampalis JS (2003) Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 143: S150-156
38. Schauer U, Hoffjan S, Bittscheidt J et al. (2002) RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J 20:1277-1283
39. Schwarze J, O'Donnell DR, Rohwedder A et al. (2004) Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 169: 801-805
40. Sigurs N, Bjarnason R, Sigurbergsson F et al. (2000) Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161: 1501-1507
41. Sigurs N, Gustafsson PM, Bjarnason R et al. (2005) Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 171: 137-141
42. Simoes EAF, Groothuis JR, Carbonell-Estrany X et al., and the Palivizumab Long-Term Respiratory Outcomes Study Group (2007) Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 151: 34-42
43. Stein RT, Sherrill D, Morgan WJ et al. (1999) Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354: 541-545
44. Sznajder M, Stheneur C, Albonico V et al.; General Pediatrics Group of the French Society of Pediatrics (2005) Respiratory development of 5- to 6-year-old children experiencing a first bronchiolitis episode before age one. Allergy Immunol 37: 392-396
45. Thomas NJ, Hollenbeak CS, Ceneviva GD et al. (2007) Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision tree model. J Pediatr Hematol Oncol 29: 227-232
46. Tortorolo L, Langer A, Polidori G et al. (2005) Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 172: 233-237
47. Van Ewijk BE, Van der Zalm MM, Wolfs TFW et al. (2005) Viral respiratory infections in cystic fibrosis. J Cyst Fibros 4: 31-36
48. Van Ewijk BE, Wolfs TFW, Aerts PC et al. (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61: 398-403
49. Van Woensel JBM, Kimpen JLL, Sprikkelman AB et al. (2000) Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. Pediatr Pulmonol 30: 92-96
50. Wat D, Doull I (2003) Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev 4: 172-177
51. Wenzel SE, Gibbs RL, Lehr MV et al. (2002) Respiratory outcome in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immunoglobulin. Am J Med 112: 627-633
52. Wilkesmann A, Ammann RA, Schildgen O et al., and the DSM RSV Ped Study Group (2007) Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26: 485-491